Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer

Liu, D.; Wu, Junrong; Shi, Guangyue; Zhou, Hongyi; Yu, Yanyan

doi:10.4238/2014.april.17.6

Cited by 21 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2014)Asian (China)192132/6060.8 (26–79)IIIA-IVPlatinum-basedOR, OSMALDI-TOF-MS ERCC1 rs3212986 rs11615 rs2298881 105 Lv, H. (2014)Asian (China)9154/3759 (34–80)IIIB-IVDDP+TAX/GEM/NVPORTaqMan-MGB GSTP1 rs1695 106 Krawczyk, P. (2014)Caucasian (Poland)11559/5661 (NR)II-IVDDP/CBP+PEMOSHRM, PCR-RFLP ERCC1 rs11615 107 Sullivan, I. (2014)Caucasian (Spain)161125/3663.7 (36–85)IIIA-IVDDP/CBP-basedOR, OSDynamic array chips ERCC1 rs3212986 rs11615, XPD rs13181 rs1799793, XPG rs1047768 rs17655, XRCC1 rs25487 rs1799782, rs25489, XPA rs1800975 108 Dong, C M. (2014)Asian (China)9238/5457 (40–6)IIIB-IVPlatinum-basedORPCR-RFLP MTHFR rs1801133 109 Liu, D. (2014)Asian (China)378297/8162.4 (36–78)I-IVDDP+GEM/DOC/NVP/TAXOR, OSPCR-RFLP XPG rs1047768 rs17655 XRCC1 rs25487 rs1799782 110 Kou, G. (2014)Asian (China)5014/3656 (45–78)IIIB-IVDDP+NVPORPCR-RFLP ERCC1 rs3212986 111 Kalikaki, A. (2015)Caucasian (Greece)10790/1760 (37–78)IIIB-IVDDP/CBP-basedOR, OS, PFSPCR-RFLP ERCC1 rs3212986, XRCC1 rs25487 112 Zou, H. Z.…”

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Data regarding genetic polymorphisms and platinum-based chemotherapy (PBC) treatment outcomes in patients with NSCLC are published at a growing pace, but the results are inconsistent. This meta-analysis integrated eligible candidate genes to better evaluate the pharmacogenetics of PBC in NSCLC patients. Relevant studies were retrieved from PubMed, Chinese National Knowledge Infrastructure and WANFANG databases. A total of 111 articles comprising 18,196 subjects were included for this study. The associations of genetic polymorphisms with treatment outcomes of PBC including overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were determined by analyzing the relative risk (RR), hazard ration (HR), corresponding 95% confidence interval (CI). Eleven polymorphisms in 9 genes, including ERCC1 rs11615 (OS), rs3212986 (ORR), XPA rs1800975 (ORR), XPD rs1052555 (OS, PFS), rs13181 (OS, PFS), XPG rs2296147 (OS), XRCC1 rs1799782 (ORR), XRCC3 rs861539 (ORR), GSTP1 rs1695 (ORR), MTHFR rs1801133 (ORR) and MDR1 rs1045642 (ORR), were found significantly associated with PBC treatment outcomes. These variants were mainly involved in DNA repair (EXCC1, XPA, XPD, XPG, XRCC1 and XRCC3), drug influx and efflux (MDR1), metabolism and detoxification (GSTP1) and DNA synthesis (MTHFR), and might be considered as potential prognostic biomarkers for assessing objective response and progression risk in NSCLC patients receiving platinum-based regimens.

show abstract

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Wang et al suggested that Chinese Han people with rs1799782 TT/CT genotype of XRCC1 gene may have increased risk of developing colorectal cancer [8]. Some previous studies suggested that XRCC1 rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy [9][10][11][12][13][14][15][16][17][18][19][20][21]. However, the results were not coincident.…”

Section: Introductionmentioning

confidence: 60%

XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy

Wang¹,

Du²,

Wang³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…The TT genotype in the ERCC5 rs1047768 polymorphism (T→C substitution at codon 46, exon 2, His→His) has been associated with increased ORR (OR=1.90; CI95%=1.10, 3.28; TT vs CC), OS (HR=0.52; CI95%=0.31, 0.96; TT vs CC) and PFS (HR=0.47; CI95%=0.22, 0.82; TT vs CC) [129]. A meta-analysis which included 5 studies with 846 cases, has recently confirmed these results for ORR (RR=1.23; CI95%=1.11, 1.36 I 2 =0%; Pheterogeneity=0.480; CT/TT vs CC) [102] while no association of rs1047768 with toxicity was found in 74 Spanish NSCLC patients [76].…”

Section: Ercc5mentioning

confidence: 99%

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

Pérez-Ramírez

Cañadas-Garre

Molina

et al. 2017

Mutation Research/Reviews in Mutation Research

View full text Add to dashboard Cite

Although platinum-based chemotherapy remains the standard treatment for advanced NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities. Genetic factors, such as single nucleotide polymorphisms (SNPs) involved in platinum pharmacodynamics, metabolism and mechanism of action, may account for inter-individual differences shown in effectiveness and toxicity. Polymorphisms in genes involved in DNA repair and others such as PI3K/PTEN/AKT and TGF-β pathways have been demonstrated to be associated with response, survival and toxicity in advanced NSCLC patients treated with platinum-based chemotherapy. Other cellular processes, like DNA methylation and proliferation have been connected with clinical outcome for platinum-based chemotherapy regimens through folate metabolism and cytokine signaling. The influence of gene polymorphisms in the NER pathway on clinical outcome has been extensively investigated in advanced NSCLC patients treated with platinum-based chemotherapy but contradictory results have been reported. The most recent and thorough meta-analyses have failed to show an association between ERCC1 C118T/C8092A and ERCC5 rs1047768 polymorphisms and response to platinum based chemotherapy. However, other polymorphisms in ERCC2 (Lys751Gln and Asp312Asn) and ERCC5 (rs2094258 and rs2296147) and have been related with overall survival (OS) and progression-free survival (PFS), respectively. The Arg194Trp and Gln399Arg polymorphisms in XRCC1, have also been extensively investigated. Their effects seem to be dependent on ethnicity, and recent meta-analyses have confirmed an association with response in Asian but not in Caucasian patients. The influence on overall response rate (ORR) of the rs861539 polymorphism in XRCC3, part of (DSB) repair pathway, has also been confirmed in a meta-analysis. Finally, SNPs in genes coding proteins of the p53, PI3K, TGF-β, membrane transporters, gluthatione metabolism enzymes and cytokine pathways have been less extensively investigated. Some polymorphisms have been reported to be associated with toxicity or clinical outcome, but data generally come from a limited number of studies and need to be confirmed.

show abstract

Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer

Cited by 21 publications

References 20 publications

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

Contact Info

Product

Resources

About